প্রকাশ: 13/01/2022
AstraZeneca said on Thursday preliminary data from a trial
it conducted on its Covid-19 shot, Vaxzevria, showed it generated a higher
antibody response against the Omicron variant and others, including Beta,
Delta, Alpha and Gamma, when given as a third booster dose.
The increased response was seen in people who were
previously vaccinated with either Vaxzevria or an mRNA vaccine, the drugmaker
said, adding that it would submit this data to regulators worldwide given the
urgent need for boosters.
AstraZeneca has developed the vaccine with researchers from
the University of Oxford, and lab studies last month found a three-dose course
of Vaxzevria was effective against the rapidly spreading new variant.
The data is the first released by the company from its
trials into boosters of its vaccine.
The company said it adds to the growing evidence that
supports a third dose of its vaccine irrespective of the primary vaccination
schedule.
"These important studies show that a third dose of
Vaxzevria after two initial doses of the same vaccine, or after mRNA or
inactivated vaccines, strongly boosts immunity against Covid-19," Oxford
Vaccine Group chief Andrew Pollard said in a statement.
A major British trial in December found that AstraZeneca's
shot increased antibodies when given as a booster after initial vaccination
with its own shot or Pfizer's, which is based on mRNA technology.
However, the study concluded that mRNA vaccines made by
Pfizer and Moderna gave the biggest boost to antibodies when given as a booster
dose.
প্রধান সম্পাদকঃ সৈয়দ বোরহান কবীর
ক্রিয়েটিভ মিডিয়া লিমিটেডের অঙ্গ প্রতিষ্ঠান
বার্তা এবং বাণিজ্যিক কার্যালয়ঃ ২/৩ , ব্লক - ডি , লালমাটিয়া , ঢাকা -১২০৭
নিবন্ধিত ঠিকানাঃ বাড়ি# ৪৩ (লেভেল-৫) , রোড#১৬ নতুন (পুরাতন ২৭) , ধানমন্ডি , ঢাকা- ১২০৯
ফোনঃ +৮৮-০২৯১২৩৬৭৭